Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.

Boyiadzis, Michael; Zhang, Mei-Jie; Chen, Karen; Abdel-Azim, Hisham; Abid, Muhammad Bilal; Aljurf, Mahmoud; Bacher, Ulrike; Badar, Talha; Badawy, Sherif M; Battiwalla, Minoo; Bejanyan, Nelli; Bhatt, Vijaya Raj; Brown, Valerie I; Castillo, Paul; Cerny, Jan; Copelan, Edward A; Craddock, Charles; Dholaria, Bhagirathbhai; Perez, Miguel Angel Diaz; Ebens, Christen L; ... (2023). Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia, 37(5), pp. 1006-1017. Springer Nature 10.1038/s41375-022-01738-3

[img] Text
s41375-022-01738-3.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)

We investigated the impact of the number of induction/consolidation cycles on outcomes of 3113 adult AML patients who received allogeneic hematopoietic cell transplantation (allo-HCT) between 2008 and 2019. Patients received allo-HCT using myeloablative (MAC) or reduced-intensity (RIC) conditioning in first complete remission (CR) or with primary induction failure (PIF). Patients who received MAC allo-HCT in CR after 1 induction cycle had 1.3-fold better overall survival (OS) than 2 cycles to CR and 1.47-fold better than ≥3 cycles. OS after CR in 2 or ≥3 cycles was similar. Relapse risk was 1.65-fold greater in patients receiving ≥3 cycles to achieve CR. After RIC allo-HCT, the number of induction cycles to CR did not affect OS. Compared to CR in 1 cycle, relapse risk was 1.24-1.41-fold greater in patients receiving 2 or ≥3 cycles. For patients receiving only 1 cycle to CR, consolidation therapy prior to MAC allo-HCT was associated with improved OS vs. no consolidation therapy. Detectable MRD at the time of MAC allo-HCT did not impact outcomes while detectable MRD preceding RIC allo-HCT was associated with an increased risk of relapse. For allo-HCT in PIF, OS was significantly worse than allo-HCT in CR after 1-3 cycles.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Bacher, Vera Ulrike

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1476-5551

Publisher:

Springer Nature

Language:

English

Submitter:

Pubmed Import

Date Deposited:

01 Nov 2022 12:48

Last Modified:

11 May 2023 00:12

Publisher DOI:

10.1038/s41375-022-01738-3

Related URLs:

PubMed ID:

36310182

BORIS DOI:

10.48350/174383

URI:

https://boris.unibe.ch/id/eprint/174383

Actions (login required)

Edit item Edit item
Provide Feedback